The ALLIANCE study is a randomized control trial comparing tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in HIV infection coinfected with hepatitis B in adults initiating first-line antiretroviral treatment. Patients were randomized to get either bictegravir/FTC/TAF vs dolutegravir plus FTC and TDF. Dr Anchalee Avihingsanon (Thai Red Cross AIDS Research Centre, Bangkok, Thailand) joins touchINFECTIOUS DISEASES to discuss the aims, design, inclusion criteria and the findings of the ALLIANCE trial.
The presentation entitled ‘Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir Disoproxil Fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE)’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
Questions:
- What were the aims, design and inclusion criteria of the ALLIANCE trial?
- What were the outcome measures of the study and how well were they achieved?
- What are the clinical implications of these findings?
Disclosures: Anchalee Avihingsanon has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
